A Chinese research team developed a new way to lower huntingtin protein indirectly, by targeting a protein called GPR52. The molecules they designed were protective in cells and in mice with HD. https://en.hdbuzz.net/298
My Questions
2020 Postcard from Palm Springs
Every year hundreds of HD researchers come together in Palm Springs to collaborate and our friend Charles Sabine provides a video summary. Grab a coffee, sit back and find out what’s new in the world of HD research.
COVID-19 and Clinical Trials
With many countries’ entire healthcare systems turned over to providing care for people with COVID illness, and many doctors and nurses diverted from research into frontline care, an impact on Huntington’s disease clinical trials is inevitable. However, all those involved are doing everything they can to minimize the impact and
RG6042 becomes Tominersen
Keen followers of the current clinical research in Huntington’s disease may will know that Roche have completed a phase 1a/2b trial and are now running a phase 2b/3a trial for their experimental drug, called RG6042. Roche have now announced a new name for the drug – Tominersen (sure to get
Postcard from Palm Springs
It’s time to make yourself a cup of coffee (or your alternative favourite beverage), sit back and watch as Charles Sabine takes us on another adventure into the international HD research world.
WHAT IS ENROLL HD?
Nicola Johns, HD Specialist and Grant Walker, Specialist Youth Advisor explain what the ENROLL study is, what it involves and how to get involved.
Roche make significant change to GENERATION HD1 clinical trial
Roche have temporarily halted recruitment to the GENERATION HD1 clinical trial (for the huntingtin lowering or gene silencing drug RG6042, initially developed by IONIS). They have decided to do this because analysis of data from the group of people who took part in the phase one trial for the drug
Huntington’s Therapeutics Conference, Palm Springs; Day One!
Our friends over at HD Buzz are attending this years’ HD Therapeutics event in Palm Springs which brings together researchers from across the world. You can read all about it at https://en.hdbuzz.net/268
Roche announce UK sites for phase three clinical trial
In December 2017 IONIS announced their phase one clinical trial for a Huntingtin Lowering or ‘gene silencing treatment’ had produced promising results. For a reminder follow the link below. They also announced that pharmaceutical company Roche purchased the licence to continue to develop this potential treatment for HD. Last year,
Cat Martin – How Scotland is Preparing for Potential HD Treatments
We recorded all of our speakers from our most recent Family Conference and will be making them available for anyone who couldn’t make it or wish to see them again. The first of these, SHA Chairperson Cat Martin – How Scotland is Preparing for Potential HD Treatments, is available now
12